ArticleScientific reports2025
Phage-antibiotic synergy to combat multidrug resistant strains of Gram-negative ESKAPE pathogens.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Genomic and Phenotypic Characterization of Two Novel Enterobacter Phages With EDTA-Enhanced Antibiofilm Activity.MicrobiologyOpen · 2026Article
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
- Phage-Antibiotic-Peptide Synergy Overcomes Biofilm-Mediated Multidrug Resistance inAntibiotics (Basel, Switzerland) · 2026Article
- Bacteriophage Challenge Drives Genomic and Proteomic Remodeling and Alters Antibiotic Resistance in a Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The cryo-EM structure of bacteriophage PRR1 and its role in conjugation inhibition.Journal of virology · 2026Article
- Evaluation of a phage-inclusive multimodal strategy for recurrent urinary tract infections.BMC microbiology · 2026Article
- Chloramphenicol and tetracycline synergize with bacteriophage SeKF_13 to inactivate antimicrobial-resistantMicrobiology spectrum · 2026Article
- Evaluation of the Therapeutic Effect of a Bovine-DerivedMicroorganisms · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Dynamics of multidrug-resistant avian pathogenic E. coli biofilm formation on various surfaces and its dispersion with phage antibiotic synergism.BMC microbiology · 2026Article
- A Triple-Modality Peptide-Antibiotic-Phage Therapy Eradicates Multidrug-ResistantbioRxiv : the preprint server for biology · 2026Article
- Synergistic disinfection by phage PLY101 and 1.3-dibromo-5.5-dimethylhydantoin (DBDMH) against resistant Proteus mirabilis.BMC microbiology · 2026Article
- Suppressing Transfer of Antibiotic Resistance by a Small RNA Virus.bioRxiv : the preprint server for biology · 2026Article
- Article
- Revitalizing actinobacteria research: an urgent response to the antimicrobial resistance crisis.Natural products and bioprospecting · 2026Article
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- Timely bespoke phage-antibiotic combination to treat refractory Pseudomonas aeruginosa mediastinitis and vascular graft infection.Nature communications · 2026Article
- Lytic bacteriophages targeting carbapenem-resistant Klebsiella pneumoniae isolated in a resource-limited Zambian laboratory.Access microbiology · 2026Article
- Searching for the perfect match: can non-antibiotic antimicrobials improve bacteriophage performance?Frontiers in cellular and infection microbiology · 2026Review
- Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bacteriophage-antibiotic-synergy (PAS) was investigated to target Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii and Enterobacter cloacae. Whole genome sequencing indicated that bacteriophage KPW17 targeting K. pneumoniae, clustered with genus Webervirus, ECSR5 targeting E. cloacae clustered with Eclunavirus, PAW33 targeting P. aeruginosa clustered with Bruynoghevirus, while ABTW1 targeting A. baumannii clustered with Vieuvirus. PAS analysis showed that the combination of ciprofloxacin (CIP) and levofloxacin (LEV) with PAW33 resulted in the synergistic eradication of all tested P. aeruginosa strains. Similarly, the combined use of doripenem (DOR) and LEV with KPW17 resulted in the synergistic eradication of the environmental and clinical K. pneumoniae strains, while the combined use of DOR and gentamicin (CN) with ECSR5 was synergistic against the clinical E. cloacae NCTC 13406. Gentamicin with ECSR5, however, only exhibited an additive effect for E. cloacae 4L, while ABTW1 with piperacillin-tazobactam (TZP) and imipenem (IPM) resulted in an indifferent interaction between the bacteriophage and tested antibiotics against the clinical A. baumannii AB3, i.e., the activity of the combination is equal to the activity of most active agent. Thus, while the observed PAS may offer an opportunity for the re-introduction or more efficient application of certain antibiotics to combat antibiotic resistance, extensive research is required to determine the optimal phage-antibiotic combinations, dosages and treatment regiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.